SDS Optic S.A. commercializes its expertise and signs an agreement with a global leader in innovative pharmaceutical therapies

SDS Optic announced the start of an update to selected elements of its strategy at the beginning of 2025. Since then, the team has been working toward the set milestones and monitoring overall progress. The Company's Management Board looks to the future with hope for new challenges and announces the implementation of further goals, including commercialization, the potential of which is confirmed by both the recently initiated cooperation and the upcoming contracts.

"For SDS Optic, collaboration with a globally renowned pharmaceutical partner confirms the potential for commercializing our technology — a milestone that would not have been possible without the contributions of the entire team, and in particular, the efforts of our current Director of Business Development. The agreement confirms that we have entered a phase of effective monetization of our competencies and demonstrates that various elements of the technologies we are developing can already be utilized by external partners." – comments Marcin Staniszewski, CEO of SDS Optic S.A.

The scope of cooperation under the signed agreement is to utilize SDS Optic's photonic technology for the detection of molecules in preclinical research projects. The task of the SDS Optic team will be to verify whether the inPROBE^® technology can ultimately assist the partner in the precise assessment of the kinetics of biological molecules in oncology.

The entry into the stage of commercialization of the Company's competencies is a consequence of many years of investment in research and development and the optimal use of the built network of international contacts by the Company's team along with external partners.

As reported by the Management Board, as part of the ongoing update of selected elements of its strategy, SDS Optic is simultaneously conducting talks with additional companies, including in other areas of its expertise — such as advanced medical devices and robotics. The Company will announce any signed agreements through press releases or, if required by the nature of the agreements, through stock exchange reports.

According to the Management Board, establishing cooperation with a global biopharmaceutical company strengthens the Company's negotiating position in ongoing talks with additional potential partners.

About SDS Optic S.A. and inPROBE

SDS Optic S.A. is an innovative biotechnology company developing a groundbreaking diagnostic technology that combines molecular biology, immunochemistry, medicine, and photonics. The company's flagship solution is the inPROBE^® platform — a micrometric fiber optic biosensor designed to enable future detection of cancer biomarkers, such as HER2, and other molecules in patient tissue. The company has initiated studies on the application of inPROBE^® technology during biopsies in breast cancer and in conjunction with endoscopic techniques in stomach cancer. Preliminary studies have confirmed the potential of the inPROBE^® microsensor for HER2 biomarker detection in patients through both in-vivo and in-vitro procedures.